Most sponsors indicated that their CROs use the contract as provided to them. However, this may be an area that requires further investigation to ensure proper understanding. This could be as simple as providing CROs and sponsors with educational tools to increase their understanding and awareness of the mCTA and its purpose.
See letter above
There is a risk associated with not adopting this – from the perspective of attracting trials. We just can’t compete on an international level, which is necessary to ensure we can attract trials. Ensuring the sustainability of clinical trials in Canada. If anyone sees a potential risk, contact the CCTCC and we would be happy to discuss.
How can we ensure that at the institution and pharma level that everyone who deal with contracts are aware of and aligned on the use of the mCTA?
Communication and dissemination of information to ensure that everyone is on board. Informational tools and an executive summary will be developed to ensure both sites and sponsors feel equipped and comfortable discussing and using the mCTA.